Fernández Casares Marcelo, Espósito Gisela, González Alejandra, Segovia Jaime, Galperín María de Los Ángeles, Del Valle Eduardo
Sección Neumonología, Hospital Profesor Alejandro Posadas, Haedo, Buenos Aires.
Medicina (B Aires). 2013;73(4):343-5.
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
抗CD20抗体利妥昔单抗应用于临床实践后，显著改善了多种血液系统疾病和自身免疫性疾病的预后。间质性肺病是利妥昔单抗治疗最严重且可能致命的并发症之一。对于接受过该药物治疗且出现呼吸困难、发热和咳嗽但无明确感染证据的患者，应考虑这一诊断。我们报告一例利妥昔单抗诱发的间质性肺病病例。
